Skip to main content

Collaborators

A network of world-class corporate and scientific collaborators to usher in a new era of patient-specific medicine

From the beginning, our goal was to establish a different model to our partnerships. We have signed seven collaboration agreements with high-profile biopharmaceutical partners, several of which are joint development deals that enable us to retain significant control of our development programs as well as participate in the future of these products. Our goal is to maximize the potential of our platforms and pipeline and leverage the broad applicability of our mRNA drug class in additional therapeutic areas beyond cancer.

 

For more information about partnering or collaborating with BioNTech please contact:

Partnered programs

On September 20, 2016, we have entered into a collaboration agreement with Genentech and F. Hoffman-La Roche Ltd, which we refer to as the Genentech Collaboration Agreement, to jointly research, develop, manufacture and commercialize certain pharmaceutical products that comprise neoepitope RNAs, or the Genentech Collaboration Products, which include our Individualized Neoantigen Specific Immunotherapy (iNeST) development candidates, for any use worldwide. Find more info on the iNeST platform here.

Together with Eli Lilly we are developing novel tumor targets and corresponding T cell receptors. The research collaboration was announced in May 2015. Learn more about our engineered cell therapy platforms here.

On November 3, 2015, we announced a licensing, co-development and co-commercialization agreement for intratumorally administered mRNA-based therapeutics for the treatment of solid tumors in humans. In March 2018, Sanofi selected the first product candidate for further development and commercialization and we exercised our option for co-development and co-commercialization of this candidate, which has entered the clinic in January 2019.

On May 19, 2015, we entered into a license and collaboration agreement with Genmab to jointly research, develop and commercialize polypeptide-based bispecific antibodies against certain target combinations for the treatment of cancer in humans worldwide. Our first product candidate DuoBody®-PD-L1x4-1BB has entered a Phase 1/2a trial in solid tumors in June 2019. For more information on our bi-specific platform programs click here.

Since May 2016, we are working with Bayer Animal Health to develop novel, first-in-class mRNA vaccines and therapeutics specifically for animal health applications.

We are collaborating with Pfizer to develop mRNA‐based vaccines for the prevention of influenza. The agreement was announced on August 16, 2018. For more information on the platform click here.

On July 10, 2018 we have formed a strategic partnership with Genevant for the development of mRNA-based therapeutics in rare diseases. For more information on our efforts in rare diseases click here.

BioNTech has an ongoing strategic partnership with Siemens to construct a fully automated, paperless and digitalized commercial cGMP-production site for individualized vaccines. Find out more on our comprehensive manufacturing capabilities here.




Scientific Collaborators

BioNTech collaborates with a large number of universities and medical centers in Europe and the U.S. to conduct its ongoing clinical studies.

TRON is a biopharmaceutical research organization that pursues the development of new diagnostics and drugs or the treatment of cancer and other severe diseases.

CI3 is a scientific, clinical and regulatory network of over 500 scientists to advance “new to the world” immunotherapies.

BioNTech is an industry partner of the DZIF (German Center for Infection Research) which aims to bridge the gaps between the discovery of new treatment approaches, preclinical development and clinical testing.

BioNTech is part of the Tumor Neoantigen Selection Alliance, launched by the non-profit organization Parker Institute for Cancer Immunotherapy which brings together the world’s best in academia, non-profits, pharma and biotech to collaborate on treating the deadliest cancers.

In October 2018, we entered into a research collaboration with Penn, under which we have the exclusive option to develop and commercialize mRNA immunotherapies for the treatment of up to 10 infectious disease indications.

We look forward to connecting with you